Patents Represented by Attorney Mary K. VanAtten

Find this attorney in the Justia Lawyer Directory

  • Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
    Patent number: 8242270
    Abstract: The invention relates to processes for preparing compounds having the formula, and crystalline forms thereof, wherein Ar is aryl or heteroaryl, L is an optional alkylene linker, and R2, R3, R4, and R5, are as defined in the specification herein, which compounds are useful as kinase inhibitors, in particular, inhibitors of protein tyrosine kinase and p38 kinase.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: August 14, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jean Lajeunesse, John D. DiMarco, Michael Galella, Ramakrishnan Chidambaram
  • Acyclic Iinhibitors
    Patent number: 7915410
    Abstract: A compound of formula I wherein R1, R2, R3, R4 and R5 are described herein.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: March 29, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: James A. Johnson, Yoon Jeon, John Lloyd, Heather Finlay
  • 1,6-dihydro-1,3,5,6-tetraaza--indacene based tricyclic compounds and pharmaceutical compositions comprising same
    Patent number: 7737279
    Abstract: The present invention provides for tricyclic compounds having the formula (I), wherein R1, R2, R5, R6, R7, and R8 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.
    Type: Grant
    Filed: May 8, 2006
    Date of Patent: June 15, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: William J. Pitts, James Kempson, Junqing Guo, Jagabandhu Das, Charles M. Langevine, Steven H. Spergel, Scott Hunter Watterson
  • Combination of Src kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
    Patent number: 7622472
    Abstract: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: November 24, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventor: Francis Y. Lee
  • 'N-(2-chloro-6-methylphenyl)-2-[[(6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites
    Patent number: 7622473
    Abstract: The present invention is directed to metabolites of ?N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, the compound of formula (I), pharmaceutical compositions thereof, and to methods of using the metabolites and the pharmaceutical compositions in the treatment of oncological and immunological disorders.
    Type: Grant
    Filed: March 15, 2006
    Date of Patent: November 24, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vinod Kumar Arora, Lisa Joy Christopher, Donghui Cui, Wenying Li
  • 8H-imidazo[4,5-D]thiazolo[4,5-B]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
    Patent number: 7557211
    Abstract: The present invention provides for thiazolopyridine-based tricyclic compounds having the formula (I), wherein R1, R2, R5 and R6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: July 7, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jagabandhu Das, James Kempson, William J. Pitts, Steven H. Spergel
  • Bicyclic and tricyclic amines as modulators of chemokine receptor activity
    Patent number: 7550500
    Abstract: The present application describes modulators of CCR3 of formula (I): A—E—NR1—G??(I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of inflammatory diseases such as asthma and other allergic diseases.
    Type: Grant
    Filed: September 13, 2005
    Date of Patent: June 23, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: John V Duncia, Joseph B Santella, III, Daniel S Gardner, Dean A Wacker
  • N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
    Patent number: 7550486
    Abstract: The present application describes modulators of chemokine receptor activity of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis, including methods of preparing and intermediates thereof.
    Type: Grant
    Filed: January 11, 2008
    Date of Patent: June 23, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Soo S. Ko, George V. Delucca
  • Process of preparing N-ureidoalkyl-piperidines
    Patent number: 7541468
    Abstract: The present application describes a process of preparing a compound of formula (IV), or salt or stereoisomer thereof: wherein Pg, at each occurrence, is independently selected from an amine protecting group; comprising the steps of reacting a compound of Formula with a reducing agent to give a compound of Formula III: reacting the compound of formula (III) with an amine of formula (IIa) using reductive amination to give the compound of formula (III)
    Type: Grant
    Filed: June 9, 2005
    Date of Patent: June 2, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventor: Percy H. Carter
  • Piperizinones as modulators of chemokine receptor activity
    Patent number: 7514430
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: July 28, 2005
    Date of Patent: April 7, 2009
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: George V. DeLucca
  • Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
    Patent number: 7491725
    Abstract: The invention relates to processes for preparing compounds having the formula, and crystalline forms thereof, wherein Ar is aryl or heteroaryl, L is an optional alkylene linker, and R2, R3, R4, and R5, are as defined in the specification herein, which compounds are useful as kinase inhibitors, in particular, inhibitors of protein tyrosine kinase and p38 kinase.
    Type: Grant
    Filed: July 29, 2005
    Date of Patent: February 17, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jean Lajeunesse, John D. DiMarco, Michael Galella, Ramakrishnan Chidambaram
  • Preparation of 2-amino-thiazole-5-carboxylic-acid derivatives
    Patent number: 7408069
    Abstract: A method for preparing a compound of the structure I,
    Type: Grant
    Filed: August 3, 2006
    Date of Patent: August 5, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Bernd Schaefer, Frank Haunert, Norbert Goetz
  • N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
    Patent number: 7351720
    Abstract: The present application describes modulators of chemokine receptor activity of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis, including methods of preparing and intermediates thereof.
    Type: Grant
    Filed: June 10, 2004
    Date of Patent: April 1, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Soo S. Ko, George V. Delucca
  • Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
    Patent number: 7329668
    Abstract: The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.
    Type: Grant
    Filed: February 24, 2004
    Date of Patent: February 12, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yuping Qiu, Makonen Belema, Xuejie Yang, Fred Christopher Zusi, William J. Pitts
  • Heterocyclic piperidines as modulators of chemokine receptor activity
    Patent number: 7312222
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: December 25, 2007
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Soo S. Ko, George V. Delucca, John V. Duncia, Joseph B. Santella, III, Dean A. Wacker
  • N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
    Patent number: 7291744
    Abstract: The present application describes modulators of chemokine receptors of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: November 6, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Soo S. Ko, Douglas G. Batt, George V. Delucca, John V. Duncia, Daniel S. Gardner, Joseph B. Santella
  • Synthesis of a benzoxazinone
    Patent number: 7205402
    Abstract: The present invention provides novel methods for the synthesis of (S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one of formula (III) which is useful as a human immunodeficiency virus (HIV) reverse transcriptase inhibitor.
    Type: Grant
    Filed: September 1, 2005
    Date of Patent: April 17, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Purushotham Vemishetti, Scott T. Chadwick, Carrie A. Costello, Sridhar Desikan, Emily A. Reiff
  • Cyclic protein tyrosine kinase inhibitors
    Patent number: 7189854
    Abstract: Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.
    Type: Grant
    Filed: May 26, 2005
    Date of Patent: March 13, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jagabandhu Das, Ping Chen, Derek J. Norris
  • Cyclic derivatives as modulators of chemokine receptor activity
    Patent number: 7183270
    Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma, processes for preparing and intermediates thereof.
    Type: Grant
    Filed: February 11, 2004
    Date of Patent: February 27, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert J. Cherney, Percy H. Carter, John V. Duncia, Daniel S. Gardner, Joseph B. Santella
  • Imidazo-fused oxazolo[4,5-?]pyridine and imidazo-fused thiazolo[4,5-?]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
    Patent number: 7176214
    Abstract: The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.
    Type: Grant
    Filed: May 18, 2004
    Date of Patent: February 13, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: William J. Pitts, Makonen Belema, Patrice Gill, James Kempson, Yuping Qiu, Claude A. Quesnelle, Steven H. Spergel, Fred Christopher Zusi